Alzheimer’s disease is one of the most important health challenges facing aging populations worldwide. The development of the next generation of Alzheimer’s disease drugs is becoming essential to face up to this challenge. We learned in Monte Carlo of new pathways identified with biomarkers, facilitating novel trial designs for studies of tau-based therapies and other disease-modifying drugs including immunotherapy.
However, we still need to overcome hurdles to speed up the development of specific new drug candidates. Again in San Diego we will address methodological issues, follow-up on new therapies and look at novel assessment tools and criteria.
Please see website for abstract submission, which opens in February.